Allakos Inc Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
Allakos Inc. is a publicly traded biotechnology company focused on developing first-in-class antibody-based therapies to treat allergic and inflammatory diseases. As a clinical-stage biopharmaceutical firm, it concentrates on antibody approaches aimed at modulating immune pathways involved in these conditions. The company is based in Redwood City, California, and began trading publicly in 2022. AK006 targets the Siglec-6 receptor on mast cells, and 2024 research published in Allergy journal describes its inhibitory effects on mast cell activation. In 2025, Allakos reduced its workforce following disappointing AK006 trial results and indicated it is exploring strategic alternatives.